The archive · Bio & Materials · Technical decision · 2014–2026
Insilico bets AI can design a working drug; rentosertib hits Phase IIa, then HKEX
Insilico's AI finds the target and designs the drug: rentosertib posts Phase IIa FVC gains, then HKEX raises HK$2.28B and Phase III starts.
Insilico Medicine
What the business is
Insilico Medicine builds the Pharma.AI platform (PandaOmics for target discovery, Chemistry42 for molecule design) and runs its own clinical pipeline, led by the TNIK inhibitor rentosertib (ISM001-055) for idiopathic pulmonary fibrosis.
Starting capital：Reuters reported a $255M financing in June 2021; $110M Series E led by Value Partners (Mar 2025) at a unicorn valuation; HKEX IPO raised HKD 2.277 billion (Dec 2025).
How it started
Founded in the US in 2014 by Alex Zhavoronkov, Insilico Medicine spent its early years publishing AI-for-biology research — a 2019 Nature Biotechnology paper showed its GENTRL model generating a DDR1 inhibitor in 21 days. It then bet the company on end-to-end generative drug discovery: target discovery, molecule design and clinical development all driven by its Pharma.AI platform.
What happened
In 2019 PandaOmics flagged TNIK as a novel IPF target; Chemistry42 designed ISM001-055, and the preclinical candidate was nominated in February 2021, 18 months after target identification. Phase 0 and two Phase I trials (New Zealand and China) showed safety, and in February 2023 the drug received FDA Orphan Drug Designation. In March 2024 Nature Biotechnology published the full journey from target to Phase II. The China Phase IIa (NCT05938920) enrolled 71 patients across 21 sites; in September 2024 Insilico reported positive preliminary results, and in November 2024 the topline showed a dose-dependent FVC improvement — +98.4 mL at 60 mg once daily versus a decline in the placebo arm — with a favorable safety profile, while a parallel US Phase IIa (NCT05975983) also read out positive.
How it ended up
In March 2025 Insilico closed a $110M Series E led by Value Partners at a unicorn valuation; on December 30, 2025 it listed on the HKEX main board (03696.HK), raising HKD 2.277 billion in the year's largest Hong Kong biotech IPO, with the public tranche oversubscribed about 1,427 times and cornerstones including Lilly, Tencent and Temasek. On July 7, 2026 the renamed rentosertib entered a Phase III trial (320 patients across 47 Chinese sites) — the first AI-discovered-target, AI-designed-molecule drug to reach late-stage testing.
Background
Insilico Medicine's bet was that generative AI could do the whole drug discovery job — find a novel disease target and design a molecule that actually works in people — not just accelerate one step. Founded in the US in 2014 by Alex Zhavoronkov, it first proved the concept in 2019 with a Nature Biotechnology paper showing its GENTRL model generating a DDR1 inhibitor in 21 days, then committed to an end-to-end platform, Pharma.AI.
The flagship program made the bet concrete. PandaOmics flagged TNIK as a novel target for idiopathic pulmonary fibrosis in 2019; Chemistry42 designed ISM001-055; and the preclinical candidate was nominated in February 2021 after screening just 78 molecules. Phase 0 and two Phase I trials established safety, and in March 2024 Nature Biotechnology published the entire journey from target identification to Phase II.
The China Phase IIa (NCT05938920) randomized 71 IPF patients across 21 sites. In September 2024 Insilico reported positive preliminary results, and the November 2024 topline showed a dose-dependent improvement in forced vital capacity — +98.4 mL at 60 mg once daily versus a decline in the placebo arm — with favorable safety, a result treated as the first clinical proof-of-concept for AI-driven drug discovery.
Capital followed the data: a $110M Series E in March 2025 made Insilico a unicorn, and on December 30, 2025 it listed on the HKEX main board as 03696.HK, raising HKD 2.277 billion in the year's largest Hong Kong biotech IPO, with cornerstones including Lilly, Tencent and Temasek. On July 7, 2026 the renamed rentosertib entered a 320-patient Phase III — the first AI-discovered, AI-designed drug in late-stage testing.
What has to be true
- End-to-end scope was the differentiator: most AI-biotech companies sell software or optimize one step; Insilico took both target and molecule through the clinic itself.
- Publishing early and repeatedly (2019 GENTRL, 2024 Nature Biotechnology) built credibility that carried fundraising when clinical data did not yet exist.
- The dose-dependent FVC result converted narrative into data: the placebo arm declined while the 60 mg arm improved by 98.4 mL over 12 weeks.
- Monetizing the platform early — out-licensing deals worth up to $2.1B with Fosun, Exelixis and Menarini, plus software deals with 13 of the top 20 pharma — funded the long clinical haul.
What can be applied
A platform bet needs a human proof point: Insilico's unicorn story became bankable only when one Phase IIa FVC number validated an AI-discovered target plus an AI-designed molecule.
Aftermath
As of 2026-09-02, Insilico Medicine (03696.HK) is public — the first AI-driven biotech under HKEX Chapter 8.05 — after raising HKD 2.277 billion. Rentosertib entered a 320-patient, 52-week Phase III in China on July 7, 2026, the most advanced AI-discovered and AI-designed drug, and its readout is treated as the field's decisive test. The company runs 30-plus pipeline programs (10 IND clearances), software collaborations with 13 of the top 20 pharma companies, out-licensing deals worth up to $2.1B, and a 249-person R&D team.
Sources
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
- A Phase 2 Readout Generates Excitement for the Potential of AI-Driven Drug Discovery
- Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
- Insilico Begins Phase III Trial of AI-Designed IPF Therapy
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card